**Title:** NEUROPEPTIDE Y AGONISTS

The present invention relates to Neuropeptide Y receptor ligands derived from alanine substitutions of the NPY24-36 amino acid sequence. The ligands may be used, for example, in the treatment or rhinitis, respiratory diseases and vasoconstriction predisposing to acute renal failure.
<table>
<thead>
<tr>
<th>Code</th>
<th>Country</th>
<th>Code</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>AL</td>
<td>Albania</td>
<td>ES</td>
<td>Spain</td>
</tr>
<tr>
<td>AM</td>
<td>Armenia</td>
<td>FI</td>
<td>Finland</td>
</tr>
<tr>
<td>AT</td>
<td>Austria</td>
<td>FR</td>
<td>France</td>
</tr>
<tr>
<td>AU</td>
<td>Australia</td>
<td>GA</td>
<td>Gabon</td>
</tr>
<tr>
<td>AZ</td>
<td>Azerbaijan</td>
<td>GB</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>BA</td>
<td>Bosnia and Herzegovina</td>
<td>GE</td>
<td>Georgia</td>
</tr>
<tr>
<td>BB</td>
<td>Barbados</td>
<td>GH</td>
<td>Ghana</td>
</tr>
<tr>
<td>BE</td>
<td>Belgium</td>
<td>GN</td>
<td>Guinea</td>
</tr>
<tr>
<td>BF</td>
<td>Burkina Faso</td>
<td>GR</td>
<td>Greece</td>
</tr>
<tr>
<td>BG</td>
<td>Bulgaria</td>
<td>HU</td>
<td>Hungary</td>
</tr>
<tr>
<td>BJ</td>
<td>Benin</td>
<td>IE</td>
<td>Ireland</td>
</tr>
<tr>
<td>BR</td>
<td>Brazil</td>
<td>IL</td>
<td>Israel</td>
</tr>
<tr>
<td>BY</td>
<td>Belarus</td>
<td>IS</td>
<td>Iceland</td>
</tr>
<tr>
<td>CA</td>
<td>Canada</td>
<td>IT</td>
<td>Italy</td>
</tr>
<tr>
<td>CF</td>
<td>Central African Republic</td>
<td>JP</td>
<td>Japan</td>
</tr>
<tr>
<td>CG</td>
<td>Congo</td>
<td>KE</td>
<td>Kenya</td>
</tr>
<tr>
<td>CH</td>
<td>Switzerland</td>
<td>KG</td>
<td>Kyrgyzstan</td>
</tr>
<tr>
<td>CI</td>
<td>Côte d’Ivoire</td>
<td>KP</td>
<td>Democratic People’s Republic of Korea</td>
</tr>
<tr>
<td>CM</td>
<td>Cameroon</td>
<td>KR</td>
<td>Republic of Korea</td>
</tr>
<tr>
<td>CN</td>
<td>China</td>
<td>KZ</td>
<td>Kazakhstan</td>
</tr>
<tr>
<td>CU</td>
<td>Cuba</td>
<td>LC</td>
<td>Saint Lucia</td>
</tr>
<tr>
<td>CZ</td>
<td>Czech Republic</td>
<td>LI</td>
<td>Liechtenstein</td>
</tr>
<tr>
<td>DE</td>
<td>Germany</td>
<td>LK</td>
<td>Sri Lanka</td>
</tr>
<tr>
<td>DK</td>
<td>Denmark</td>
<td>LR</td>
<td>Liberia</td>
</tr>
<tr>
<td>EE</td>
<td>Estonia</td>
<td>LS</td>
<td>Lesotho</td>
</tr>
<tr>
<td>SI</td>
<td>Slovenia</td>
<td>SK</td>
<td>Slovakia</td>
</tr>
<tr>
<td>SN</td>
<td>Senegal</td>
<td>SZ</td>
<td>Swaziland</td>
</tr>
<tr>
<td>TD</td>
<td>Chad</td>
<td>TG</td>
<td>Togo</td>
</tr>
<tr>
<td>TJ</td>
<td>Tajikistan</td>
<td>TM</td>
<td>Turkmenistan</td>
</tr>
<tr>
<td>TR</td>
<td>Turkey</td>
<td>TT</td>
<td>Trinidad and Tobago</td>
</tr>
<tr>
<td>UA</td>
<td>Ukraine</td>
<td>UG</td>
<td>Uganda</td>
</tr>
<tr>
<td>US</td>
<td>United States of America</td>
<td>UK</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>UZ</td>
<td>Uzbekistan</td>
<td>VN</td>
<td>Viet Nam</td>
</tr>
<tr>
<td>YU</td>
<td>Yugoslavia</td>
<td>ZW</td>
<td>Zimbabwe</td>
</tr>
<tr>
<td>ZW</td>
<td>Zimbabwe</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Neuropeptide Y Agonists

Field of invention

The present invention relates to peptides which mimic certain of the biological activities of Neuropeptide Tyrosine (NPY) at specific NPY receptors that modulate neuronal release of physiologically active substances. These receptors are often located on neurones at neuroeffector junctions and, in some tissues and species, have been classified as of the NPY Y2 receptor subtype. In addition, the present invention relates to pharmaceutical compositions including, as the active ingredient, these peptides and to methods of treatment involving the administration of these compositions.

Background of invention

Neuropeptide Y, a 36 amino acid peptide belonging to the pancreatic polypeptide family, was first isolated from porcine brain in 1982 (Tatemoto et al., 1982) and has since been identified in most sympathetic postganglionic neurons innervating the cardiovascular system, where it is co-localised with noradrenaline (Potter, 1988). In the cardiovascular system it raises blood pressure by an action on postjunctional neuropeptide Y receptors (Dahlöf et al., 1985; Potter, 1985; Revington et al., 1987; Potter and McCloskey, 1992) and inhibits neurotransmitter release - both acetylcholine (Revington et al., 1987; Warner and Levy, 1989) and noradrenaline (Edvinsson, 1988) - by acting on prejuncti onal neuropeptide Y receptors. Receptors for neuropeptide Y are also located on sensory nerve terminals and their activation can modulate local neurogenic responses (Grundemar et al., 1990; 1993). These two receptor subtypes have been called neuropeptide Y Y1 (postjunctional) and neuropeptide Y Y2 (prejunctional) on the basis of the different responses to a truncated analog of the related peptide YY-(13-36), when compared with neuropeptide Y in in vitro assay systems (Wahlestedt et al., 1986). Apart from these historically well-defined neuropeptide Y receptors the existence of a number of other subtypes (Y3, Y4, Y5, Y6 and Y7) have been suggested on pharmacological grounds and details of the cloning of receptors corresponding to Y1, Y2, Y4 and Y5 have been published (Herzog et al., 1992; Gerald et al., 1995; Bard et al., 1995; Gerald et al., 1996). The distribution and physiological significance of these various receptor subtypes has yet to be defined. Although some controversy has existed about the selectivity of truncated forms of neuropeptide Y for
one or other receptor subtype (Potter et al., 1989), the emerging picture supports the initial classification into pre- and postjunctinal receptor subtypes. Cell lines have been developed which express one or other neuropeptide Y receptor subtype and the development of receptor-selective analogs of neuropeptide Y has focused mainly on binding characteristics in these cell lines (Sheikh et al., 1989; Aakerlund et al., 1990; Fuhlendorff et al., 1990). More recently, a cDNA encoding the neuropeptide Y \( Y_1 \) receptor has been cloned and cell lines expressing the cloned receptor have been analyzed for both specific binding of neuropeptide Y analogs (Herzog et al., 1992) and functional responses elicited by specific analogs. From such binding studies, combined with subsequent studies in vivo, two analogs have been classified as acting specifically on the postjunctural (neuropeptide Y \( Y_1 \) ) receptor. These neuropeptide Y \( Y_1 \), selective analogs, (Pro\(^{34}\)) neuropeptide Y and (Leu\(^{31}, \text{Pro}^{34}\)) neuropeptide Y, mimic the action of neuropeptide Y in raising blood pressure, and also share similar binding to cell lines expressing only neuropeptide Y \( Y_1 \) receptors e.g. the human neuroblastoma cell line SK-N-MC and fibroblast lines expressing the cloned neuropeptide Y \( Y_1 \) receptor (Herzog et al., 1992). Neither exhibits the neuropeptide Y \( Y_2 \) receptor action of inhibiting cardiac vagal action in vivo, a manifestation of inhibition of acetylcholine release (Potter et al., 1991; Potter and McCloskey, 1992).

Activation of neuronal prejunctural NPY receptors generally inhibits nerve activity, reducing the release of neurotransmitters in response to nerve impulses and in response to local factors acting to release neurotransmitters (Wahlestedt et al., 1986).

NPY-containing neurons are evident in the nasal mucosa of various species including man, often associated with glandular acini and blood vessels (Baraniuk et Al., 1990; Grunditz et. al., 1994). Stimulation of the parasympathetic nerve supply to the nasal mucosa (vidian nerve) in dogs increases blood flow in the region and the major part of this effect is atropine resistant. Intravenous administration of NPY reduces vasodilation due to parasympathetic nerve stimulation, an effect that was not mimicked by the NPY \( Y_1 \)-selective agonist [Leu\(^{31}, \text{Pro}^{34}\)]NPY, but was mimicked by administration of the NPY \( Y_2 \)-receptor agonist N-acetyl[Leu\(^{28},\text{Leu}^{31}\)]NPY(24-36) (Lacroix et al., 1994). This is consistent
with a prejunctional NPY Y2-like receptor-mediated inhibition of transmitter release from parasympathetic nerve terminals.

The prejunctional or neuropeptide Y Y2 receptor classification was based on actions of peptide YY (13-36) but in many systems this molecule, as well as neuropeptide Y-(13-36), does exhibit pressor activity (Rioux et al., 1986; Lundberg, et al., 1988; Potter et al., 1989). This has been interpreted by some to indicate that in some vascular beds there are two types of neuropeptide Y receptor (both neuropeptide Y Y1 and neuropeptide Y Y2) on postjunctional membranes (Schwartz et al., 1989). However the lack of selectivity of these molecules may be due to retention of partial agonist activity on Y1 receptors, which permits them to evoke a reduced functional response. We have previously described a 13-36 analog of neuropeptide Y, (Leu[17], Glu[19], Ala[21], Ala[22], Glu[23], Leu[28], Leu[31]) neuropeptide Y-(13-36) (ANA neuropeptide Y-(13-36)) which displayed prejunctional activity equivalent to the whole neuropeptide Y molecule in studies in vivo (Potter et al., 1989). However, this analog still retained significant pressor activity, or neuropeptide Y Y1 receptor-mediated interactions.

We have also previously described analogs of neuropeptide Y which mimic the action of neuropeptide Y in inhibiting cardiac vagal action but have no pressor action. Consistent with these functional responses are binding studies with one analog, N-acetyl [Leu[28], Leu[31]] neuropeptide Y-(24-36), which showed significant affinity for the neuropeptide Y Y2 receptor subtype expressed on the human neuroblastoma cell line SMS-KAN, but no affinity for the neuropeptide Y Y1 receptor type expressed on the human cell line SK-N-MC (Potter et al., 1994). In addition, this analog did not stimulate the human neuropeptide Y Y1 receptor expressed in fibroblast cells to induce an increase in cytosolic calcium, although the receptor responds to intact neuropeptide Y.

Disclosure of invention

The present inventors have now developed novel peptides that mimic responses attributed to activation of neuropeptide Y Y2-like receptors. In in vitro assays these agonists show high affinity at neuropeptide Y Y2 receptors and have low affinity for NPY Y1 receptors. In in vivo assays the new agonists exhibit similar or enhanced NPY Y2-receptor-like agonist activity when compared with N-acetyl [Leu[28], Leu[31]] neuropeptide Y-(24-36)
and they show no pressor or Y₁-receptor activity at doses eliciting maximal neuropeptide Y Y2-like agonist action.

Accordingly, in the first aspect the present invention consists in a ligand for a neuropeptide Y receptor having the formula:

\[
X_1-X_2-X_3-X_4-X_5-X_6-X_7-X_8-X_9-X_{10}-X_{11}-X_{12}-X_{13}-X_{14}-X_{15}
\]

wherein
X₁ is H, R₁-CO or one or two naturally occurring amino acids
X₂ is Leu, Ile, Val, Nle, Sar, Gly, Ala, Aib, D-Leu, D-Ile, D-Val, D-Ala or D-Nle;
X₃ is Arg, Lys, Orn, Ala, Dbu or His;
X₄ is His, Lys, Arg, Ala, Gly, Ser, Thr, Asn, Gln or Aib;
X₅ is Tyr, Phe, Ala, Gly, Ser, Thr, Asn, Gln or Aib;
X₆ is Leu, Ile, Val, Ala, Arg or Nle;
X₇ is Asn, Ala or Gln;
X₈ is Leu, Ile, Val, Ala, Aib or Nle;
X₉ is Leu, Ile, Val, Ala, Aib or Nle;
X₁₀ is Thr, Ala or Ser;
X₁₁ is Arg, Lys or Orn;
X₁₂ is Gln, Pro or Asn;
X₁₃ is Arg, Lys or Orn;
X₁₄ is Tyr, Phe, His, Trp, D-Tyr, D-Phe, D-His or D-Trp;
X₁₅ is OH, NH₂, NHR₂, NR₃R₄ or one or two naturally occurring amino acids with the terminal amino acid being in the normal or amide form;

wherein R₁, R₂, R₃ and R₄ are independently alkyl groups, straight, branched or alicyclic in structure; and

wherein at least one of X₂ to X₁₀ is Ala.

Abbreviations:

Sar: Sarcosine or N-methylglycine
Aib: Aminoisobutyric acid
Orn: Ornithine
Dbu: Diaminobutyric acid

In a preferred embodiment, at least two groups selected from X₂, X₄, X₅, X₈ and X₉ are Ala. In a particularly preferred embodiment, X₂ and X₅ are Ala.
In a further preferred embodiment, R1 is an alkyl group selected from methyl, ethyl, n-butyl, t-butyl, cyclohexyl and other alkyl groups with 10 or less carbon atoms.

In a further preferred embodiment, R2, R3 and R4 are alkyl groups selected independently from methyl, ethyl, isopropyl, n-butyl, cyclohexyl and other alkyl groups with 10 or less carbon atoms.

In a further preferred embodiment of the present invention the ligand is

\[
\text{Ac-Ala-Arg-Ala-Ala-Leu-Asn-Ala-Ala-Thr-Arg-Gln-Arg-Tyr-NH}_2 \text{ or }
\]

\[
\text{Ac-Ala-Arg-His-Tyr-Leu-Asn-Leu-Leu-Thr-Arg-Gln-Arg-Tyr-NH}_2 \text{ or }
\]

\[
\text{Ac-Leu-Ala-His-Tyr-Leu-Asn-Leu-Leu-Thr-Arg-Gln-Arg-Tyr-NH}_2 \text{ or }
\]

\[
\text{Ac-Leu-Arg-Ala-Tyr-Leu-Asn-Leu-Leu-Thr-Arg-Gln-Arg-Tyr-NH}_2 \text{ or }
\]

\[
\text{Ac-Leu-Arg-His-Ala-Asn-Leu-Leu-Thr-Arg-Gln-Arg-Tyr-NH}_2 \text{ or }
\]

\[
\text{Ac-Leu-Arg-His-Tyr-Leu-Ala-Leu-Thr-Arg-Gln-Arg-Tyr-NH}_2 \text{ or }
\]

\[
\text{Ac-Leu-Arg-His-Tyr-Leu-Asn-Ala-Leu-Thr-Arg-Gln-Arg-Tyr-NH}_2 \text{ or }
\]

\[
\text{Ac-Leu-Arg-His-Tyr-Leu-Asn-Leu-Leu-Thr-Arg-Gln-Arg-Tyr-NH}_2 \text{ or }
\]

\[
\text{Ac-Ala-Arg-His-Ala-Leu-Ala-Leu-Thr-Arg-Gln-Arg-Tyr-NH}_2 \text{ or }
\]

\[
\text{Ac-Leu-Arg-Ala-Ala-Leu-Asn-Ala-Thr-Arg-Gln-Arg-Tyr-NH}_2 \text{ or }
\]

\[
\text{Ac-DLeu-Arg-Ala-Ala-Leu-Asn-Ala-Thr-Arg-Gln-Arg-Tyr-NH}_2 \text{ or }
\]

\[
\text{Ac-DLeu-Arg-Ala-Ala-Leu-Asn-Ala-Thr-Arg-Gln-Arg-Phe-NH}_2 \text{ or }
\]

\[
\text{Ac-DLeu-Arg-Ala-Ala-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Phe-NH}_2 \text{ or }
\]

\[
\text{Ac-DLeu-Arg-Ala-Aib-Leu-Asn-Ala-Aib-Thr-Arg-Gln-Arg-Phe-NH}_2 \text{ or }
\]

\[
\text{Ac-DLeu-Lys-Ala-Ala-Leu-Asn-Ala-Ala-Thr-Lys-Gln-Lys-Phe-NH}_2 \text{ or }
\]

\[
\text{Butyryl-Leu-Arg-Ala-Ala-Leu-Asn-Ala-Thr-Arg-Gln-Arg-Phe-NH}_2 \text{ or }
\]

\[
\text{Ac-Ala-Arg-Ala-Ala-Leu-Leu-Thr-Arg-Gln-Arg-DTyr-NH}_2 \text{ or }
\]

\[
\text{Ac-Ala-Arg-Ala-Leu-Gln-Ile-Leu-Ser-Arg-Asn-Arg-Tyr-NH}_2 \text{ or }
\]

In a preferred embodiment of this invention the neuropeptide Y receptor is a neuropeptide Y Y2-like receptor. By "neuropeptide Y Y2-like receptor" we mean a receptor which shares pharmacological properties with the human neuropeptide Y Y2 receptor. Such receptors may modulate the release of neurotransmitters such as acetylcholine and noradrenaline and may modulate the release of effectors from sensory nerves. Some NPY receptor subtypes, for example Y5, can be activated by
ligands with high potency at NPY Y2 receptors but low potency at NPY Y1 receptors (Gerald et al., 1996) and are therefore Y2-like. In a most preferred embodiment, the receptor is a neuropeptide Y Y2 receptor.

The ligands of the invention may be in multimeric form; i.e. they may be in dimeric or trimeric form.

It will be appreciated by those skilled in the art that a number of modifications may also be made to the peptides of the present invention without deleteriously affecting the biological activity of the peptide. This may be achieved by various changes, such as insertions and substitutions, either conservative or non-conservative in the peptide sequence where such changes do not substantially decrease the biological activity of the peptide.

Modifications of the peptides contemplated herein include, but are not limited to, modifications to side chains, incorporation of unnatural amino acids and/or their derivatives during peptide synthesis and the use of crosslinkers and other methods which impose conformational constraints on the peptides.

Examples of side chain modifications contemplated by the present invention include modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH₄; amidation with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2,4,6-trinitrobenzene sulphonic acid (TNBS); acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxal-5'-phosphate followed by reduction with NaBH₄.

The guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal.

The carboxyl group may be modified by carbodiimide activation via O-acylisourea formation followed by subsequent derivitisation, for example, to a corresponding amide.

Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-bitrobenzyl bromide or sulphenyl halides. Tyrosine residues on the
other hand, may be altered by nitration with tetrannitromethane to form 3
nitrotyrosine derivative.

Modification of the imidazole ring of a histidine residue may be
accomplished by alkylation with iodoacetic acid derivatives or N-
carbethoxylated with diethylpyrocarbonate.

Examples of incorporating unnatural amino acids and derivatives
during peptide synthesis include, but are not limited to, use of norleucine,
4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 6-
aminoheptanoic acid, t-butylglycine, norvaline, phenylglycine, ornithine,
sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid; 2-thienyl alanine
and/or D-isomers of amino acids.

As a further example, it is possible in the present invention to
replace the residue at X14 by other non-natural amino acids with
hydrophobic side chains such as Cha (beta-cyclohexyl-L-alanine), Nal
(beta-(2-naphthyl)-alanine), Phg (L-phenylglycine), Tic (L-1,2,3,4-
tetrahydroisoquinoline 3-carboxylic acid), Thi (beta-(2-thienyl)-L-alanine),
or their D-isomers, without substantially altering the biological activity.

It may also be possible to add various groups to the peptide of the
present invention to confer advantages such as increased potency or
extended half life in vivo without substantially decreasing the biological
activity of the peptide. It is intended that such modifications to the
peptide of the present invention which do not result in a decrease in
biological activity are within the scope of the present invention.

The ligands of the present invention may be useful in treatment of
the following conditions:
- Conditions related to inflammation (such as nasal inflammation,
rhinitis including allergic and vasomotor, asthma, arthritis).
- Conditions related to neurogenic inflammation (such as
migraine, headache, inflammation of the eye, rhinitis, etc.).
- Rhinitis - vasomotor rhinitis.
- Respiratory diseases (such as pulonmory congestion, asthma,
upper respiratory tract inflammation).
- Sleep disorders.
- Conditions related to increased sympathetic nerve activity.
- Disorders related to sexual dysfunction and reproductive
disorders.
- Disorders or diseases pertaining to the heart, blood vessels or
the renal system (such as vasospasm, heart failure, shock, cardiac
hypertrophy, increased blood pressure, angina, myocardial infarction,
sudden cardiac death, arrhythmia, peripheral vascular disease, renal
failure, etc.).

- Conditions related to increased sympathetic nerve activity (e.g.
during or after coronary artery surgery, and operations and surgery in the
gastrointestinal tract).

- Cerebral diseases and diseases related to pain or nociception.

- Diseases related to the central nervous system (e.g. cerebral
infarction, neurodegeneration, epilepsy, stroke, cerebral vasospasm,
depression, anxiety or dementia).

- Diseases related to abnormal gastrointestinal motility and
secretion (e.g. Crohn's disease).

- Diseases and conditions affecting the urinogenital system (e.g.
urinary incontinence).

- Abnormal drink and food intake disorders (such as obesity,
anorexia, bulimia etc.).

In a second aspect, therefore, the present invention consists in a
composition for use in relieving nasal congestion or treating
vasoconstriction predisposing to acute renal failure, anti-hypertensive
conditions, cardiovascular disorders, conditions related to pulmonary
congestion, inflammation, neurogenic inflammation, sleep disorders,
conditions related to increased sympathetic nerve activity, diseases
related to the central nervous system, conditions related to pain or
nociception, diseases related to gastrointestinal motility and secretion,
obesity, or Alzheimer's disease, or as an anti-psychotic, the composition
including the peptide of the first aspect of the present invention and a
pharmaceutical carrier.

In a third aspect the present invention consists in a method of
relieving nasal congestion, attenuating cardiac vagal action, treating
vasoconstriction predisposing to acute renal failure, hypertension,
cardiovascular disorders, conditions related to pulmonary congestion,
inflammation, neurogenic inflammation, sleep disorders, conditions related
to increased sympathetic nerve activity, diseases related to the central
nervous system, conditions related to pain or nociception, diseases related
to gastrointestinal motility and secretion, obesity, or Alzheimer's disease in a subject comprising administering to the subject an effective amount of the composition of the second aspect of the present invention.

In a preferred embodiment of the third aspect of the present invention the subject is suffering from nasal congestion, pulmonary congestion or vasoconstriction predisposing to acute renal failure. In a further preferred embodiment the composition is administered as a nasal spray.

The active compound may be administered in a convenient manner such as by the oral, intravenous (where water soluble), intramuscular, subcutaneous, intranasal, intradermal or suppository routes or implanting (eg using slow release molecules). It may also be inhaled (dry or in. solution) into the lungs. Depending on the route of administration, the active ingredients may be required to be coated in a material to protect said ingredients from the action of enzymes, acids and other natural conditions which may inactivate said ingredients. For example, low lipophilicity of peptides might allow them to be destroyed in the gastrointestinal tract by enzymes capable of cleaving peptide bonds and in the stomach by acid hydrolysis. In order to administer peptides by other than parenteral administration, they could be coated by, or administered with, a material to prevent its inactivation. For example, peptides may be administered in a solvent, in liposomes, or co-administered with enzyme inhibitors. Enzyme inhibitors include pancreatic trypsin inhibitor, diisopropylfluorophosphate (DFP) and trasylol. Liposomes include water-in-oil emulsions as well as conventional liposomes.

The active compounds may also be administered parenterally. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the
conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example glycerol, propylene glycol and liquid polyethylene glycol, and the like), suitable mixtures thereof and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thiomersal and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminium monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various other ingredients as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilised ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients. In the case of sterile powders for use as such or for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze-drying technique which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.

In order that the nature of the present invention may be more clearly understood, preferred forms thereof will now be described with reference to the following examples and Figure in which:-

Figure 1 shows the effect of Ac[Ala24, Ala27, Leu28, Leu31]NPY(24-36) on increased renal vascular resistance in rats elicited by electrical stimulation of the renal sympathetic nerve.
Materials and Methods

In vivo

Experiments were carried out on adult rats (Wistar) of both sexes (250-350g), anaesthetised with sodium pentobarbitone (Nembutal, Boehringer-Ingelheim; 60 mg/kg, i.p.). The trachea was cannulated and the animal artificially ventilated. The femoral vein was cannulated for administration of peptides and further doses of anaesthetic. The left femoral artery was cannulated to record arterial pressure. Both vagus nerves were cut. This was done to eliminate vagally-mediated reflex effects on the heart which can occur when blood pressure is raised by neuropeptide Y. The cardiac end of the right vagus nerve was stimulated every 30 s with a 6 s train of supramaximal stimuli (2 Hz, 1 ms; 7V) using an isolated, square-wave stimulator (Grass Instruments). The frequency was chosen to increase pulse interval by approximately 100 ms, a submaximal effect on this variable. The electrocardiogram was measured using needle electrodes and monitored on one channel of an oscilloscope. Pulse interval (the period between successive beats of the heart) was recorded beat-by-beat by triggering from ECG. Pulse interval and arterial pressure were recorded on the pen recorder.

Dose-response curves were constructed from group data for all rats. Because of the long time-course of action of the peptides tested, not all peptides were given to each rat. Usually however, each rat received neuropeptide Y and two other peptides.

As an indication of prejunctional activity two parameters were measured; the maximum percent inhibition of the increase in pulse interval evoked by stimulation of the vagus nerve following injection of peptide and the time to half recovery of this effect (T50). For pressor action, an indicator of postjunctional activity, two parameters were also measured; the peak pressor response following injection of peptide and the duration of the increase in blood pressure. These indices give a reliable measure of the actions of a peptide at pre- and postjunctional sites, and have been used previously in this laboratory for this purpose; Potter et al., 1989; Potter et al., 1991). Results were analysed using a one-way ANOVA.

Methods for experiments on kidney blood flow (in vivo).

Experiments were carried out in six, adult, mongrel dogs of both sexes weighing between 18 and 26 kg. The dogs were anaesthetised with a
bolus injection of sodium pentobarbitone (36 mg/kg intravenous; Nembutal, Boehringer Ingelheim) and then maintained on an infusion (2-3 mg/kg/hr). The animal was artificially ventilated, maintained at constant temperature and blood pressure and heart rate were monitored continuously.

The left kidney was exposed retroperitoneally and renal arterial blood flow was monitored continuously (Pernow & Lundberg, 1989a), using a transonic flow probe (Transonic System Inc., N.Y.). Postganglionic nerves to the kidney were isolated, cut and placed over bipolar, platinum electrodes for stimulation (1-10 Hz, 5-10 V, 1-5 msec). Noradrenaline and neuropeptide Y have been shown to co-exist in the kidney and are released together on stimulation of the renal nerves (Pernow & Lundberg, 1989b).

The renal nerve was stimulated over a range of frequencies (1-10 Hz) for 30 secs and a frequency-response curve constructed. The responses were measured at the peak change in flow. These frequency-response relationships were examined before and after a bolus dose (40 nmol/kg) of the NPY Y2 receptor agonist. Responses were reported as change in vascular resistance.

Methods for binding experiments (in vitro)

Cell culture

SK-N-MC cells expressing the human Y1 receptor and SMS-MSN cells expressing the human Y2 receptor were obtained from the ATCC. They were cultured in 1:1 DMEM:Ham's F12 medium (ICN) containing 10% fetal calf serum, 0.1% non-essential amino acids, 0.2 mM glutamine, and 0.056% sodium bicarbonate. Confluent cells were harvested in scraping and pellets were stored at -80°C. On the day of use cells were thawed, washed once in binding buffer salts, passed several times through a 22 ga. needle, and the protein content was assayed using bicinchoninic acid (BCA kit, Pierce). Cell volume was adjusted to give a protein concentration of 200-400 µg/ml (SMS-MSN cells) or 400-800 µg/ml (SK-N-MC cells), and BSA and protease inhibitors were added.

Receptor binding assays

Receptor binding assays were performed in Multiscreen FC plates (Millipore) [Gregor et al., 1996], pre-coated overnight at 4°C with 0.5% PVP / 0.1% Tween-20 [Scott et al, 1995] to prevent non-specific binding. Just before use, plates were filtered and washed twice with 50 mM Tris-HCl pH 7.4 / 0.1% BSA. 30 pM [125i]NPY (Amersham), competitors (10 pM to 1 µM)
and cells (10-20 µg for SMS-MSN or 20-40 µg for SK-N-MC) were incubated for 2.5 h at room temp in a total volume of 200 µl, in binding buffer containing 50 mM Tris-HCl pH 7.4, 115 mM NaCl, 15 mM KCl, 5 mM CaCl2, 2 mM MgSO4, 1.25 mM KH2PO4, 25 mM NaHCO3, 10 mM glucose, 0.1% BSA, 4 mg/ml bacitracin, and 0.5 mM PMSF [Tschöpl et al., 1993]. Binding was terminated by filtration. Filters were washed twice by rapid filtration with 200 µl volumes of 50 mM Tris-HCl pH 7.4 / 0.1% BSA at 2°C, and counted on an LKB gamma counter. Specific binding was analysed by non-linear regression using a single-site fitting function (Graphpad Prism). Nonspecific binding was defined by binding in the presence of 1 µM competitor.

*Peptide Synthesis and Purification*

Peptide amides were synthesized by standard Boc or Fmoc solid-phase chemistry.

Boc synthesis was carried out using polystyrene based MBHA resin. Acetylation at the end of the synthesis was carried out using acetic anhydride in methanol. Peptides were cleaved by hydrogen fluoride containing phenol (1.3 g to 10 ml) as a scavenger and extracted into an aqueous phase (30% aqueous acetonitrile v/v). Scavengers were washed with ether and the crude aqueous extracts were then lyophilised to yield crude peptide. Side chain protection groups chosen for each amino acid were removed during the cleavage process. Peptides were purified by ion-exchange and reversed phase HPLC (high pressure liquid chromatography) to 95%.

Fmoc synthesis was carried using tentagel SRAM resin. Acetylation is performed as the last cycle using AcONSu (N-succinimidy1 ester of acetic acid). Peptides were cleaved by 95% TFA containing thioanisole and p-cresol as scavengers and extracted into an aqueous phase containing 30% acetonitrile. Scavengers were washed with ether and the crude aqueous extracts were then lyophilised to yield crude peptides, which were purified by ion-exchange and reversed phase HPLC to 95%. Peptides were analysed for amino acid composition, and for correct molecular ion by electrospray mass spectrometry. Purity was estimated by both analytical HPLC and CE (capillary electrophoresis). All peptides carrying net positive charges were presented as acetate salts and peptide contents in all samples were determined based on the Pierce standard used in Picotag amino acid analysis.
Results and Discussion

Novel peptides, based on the amino acid sequence of neuropeptide Y in the region encompassed by amino acids 24-36, have been synthesized and tested for in vivo activity.

Of all the molecules tested in vivo in rats, only NPY raised blood pressure significantly in a dose-dependent manner. None of the other compounds significantly changed blood pressure at the doses tested. This is indicative of a lack of direct effect on neuropeptide Y receptors associated with increases in blood pressure, the Y1 receptor subtype.

Administration of all compounds listed in Table 1 dose-dependently inhibited the reduction in heart rate due to electrical stimulation of the vagus nerve. Notably, substitution of Ala at any position of 24 to 31 in Ac[Leu28,Leu31]NPY(24-36) resulted in enhanced potency (reduction in EC50) as an inhibitor of the effect of vagal stimulation on heart rate. This inhibition of the effect of vagal stimulation indicates a reduction in release of acetylcholine from the parasympathetic innervation to the heart and has been attributed to stimulation of NPY Y2 receptors (Potter et al., 1994). Ala substitutions at positions 24 to 31 were all associated with high affinity for NPY Y2 receptors and low affinity for NPY Y1 receptors (Table 1).

Unexpectedly, there was no direct correlation between in vivo activity in inhibiting vagal nerve mediated reductions in heart rate and affinity for Y2 receptors and this could indicate enhanced in vivo stability of some compounds. The enhancement of biological activity by Ala substitution in any one of 8 of 13 amino acid residues of Ac[L28,L31]NPY24-36 was unexpected. Even more surprising was the finding that multiple Ala substitutions to produce compounds such as Ac[A24,A27,L28,L31]NPY24-36, Ac[A26,A27,L28,L31]NPY24-36 and Ac[A24,26,27,30,31,L28]NPY24-36 also enhanced in vivo activity at Y2 receptors. The observation that 5 residues of
Table 1

Activities *in vivo* (change in pulse interval (P1: activity at Y2-like receptors) and in blood pressure (BP: activity at Y1 receptors) in anaesthetised rats) and affinities for Y1 and Y2 receptors *in vitro* of a series of peptides.

<table>
<thead>
<tr>
<th>Compound</th>
<th>EC50 (nmole)</th>
<th>Increase in BP (rel to NPY)</th>
<th>IC50 (nM) SMS-MSN</th>
<th>IC50 (nM) SK-N-MC</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPY</td>
<td></td>
<td>1</td>
<td>0.66</td>
<td>10.96</td>
</tr>
<tr>
<td>AcNPY 24-36</td>
<td>3.98</td>
<td>0+</td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td>Ac[L28,L30]NPY24-36</td>
<td>1.26</td>
<td>0+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ac[A24,L28,L31]NPY24-36</td>
<td>0.46</td>
<td>0+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ac[A25,L28,L31]NPY24-36</td>
<td>1.58</td>
<td>0+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ac[A26,L28,L31]NPY24-36</td>
<td>1.26</td>
<td>0+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ac[A27,L28,L31]NPY24-36</td>
<td>0.52</td>
<td>0+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ac[A28,L31]NPY24-36</td>
<td>2.75</td>
<td>0+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ac[L28,A29,L31]NPY24-36</td>
<td>1.48</td>
<td>0+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ac[L28,A30,L31]NPY24-36</td>
<td>0.39</td>
<td>0+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ac[L28,A31]NPY24-36</td>
<td>0.78</td>
<td>0+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ac[L28,L31,A32]NPY24-36</td>
<td>6.46</td>
<td>0+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ac[A24,A27,L28,L31]NPY24-36</td>
<td>0.89</td>
<td>0+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ac[A24,25,27,30,31,L28]NPY24-36</td>
<td>0.56</td>
<td>0+</td>
<td>3.16</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>Ac[A25,R28,L31]NPY24-36</td>
<td>1.95</td>
<td>0+</td>
<td>0.1</td>
<td>691.83</td>
</tr>
<tr>
<td>Ac[L28,L31]NPY24-36</td>
<td>3.16</td>
<td>0+</td>
<td>3.90</td>
<td>&gt;100</td>
</tr>
<tr>
<td>Ac[A26,27,L28,31]NPY24-36</td>
<td>1</td>
<td>0+</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

†: No response to 10 nmole dose
13 could be replaced by Ala means that the comparatively extended side 
chains in these positions (24,26,27,30,31) are not essential to the 
maintenance of efficacy or affinity at NPY Y2 receptors. This is surprising as 
the replaced amino acid residues are diverse in structure and properties, two 
are aromatic (His, Tyr), one with a carboxamide side chain and the rest 
having aliphatic side chains carrying 3 carbon atoms more than Ala. 
Furthermore the affinity of the multi-Ala substituted compounds at NPY Y2 
receptors was similar to, or better than, that of Ac[L28,L31]NPY24-36, even 
though substitution of Leu24 or of His26 alone by Ala resulted in an 
apparent reduction in affinity. Such maintenance, or enhancement of 
activities could not be predicted. The multiple Ala containing compound 
Ac[A24,A27,L28,L31]NPY24-36 was assessed for its ability to inhibit the 
increase of renal vascular resistance elicited by renal nerve stimulation. A 
40 nmol dose of this compound, that exerted no direct effect on the 
circulation (Table 1), almost completely inhibited the effect of nerve 
stimulation (Figure 1) demonstrating an inhibition of transmitter release 
from the stimulated nerve. This compound exhibits a high affinity for NPY 
Y2 receptors, so although receptors mediating inhibition of transmitter 
release from renal nerves have not been identified they can be characterised 
as Y2-like.

The in vivo observations demonstrate that these compounds have 
general ability to inhibit neurotransmitter release from sympathetic and 
parasympathetic nerves and the agents would be expected to have activity in 
circumstances where inhibition of neurotransmission, of any type, was 
desirable. Examples of circumstances where inhibition of neurotransmission 
may be desirable are conditions such as nasal congestion, pulmonary 
congestion and neurogenic inflammation.

It will be appreciated by persons skilled in the art that numerous 
variations and/or modifications may be made to the invention as shown in 
the specific embodiments without departing from the spirit or scope of the 
invention as broadly described. The present embodiments are, therefore, to 
be considered in all respects as illustrative and not restrictive.
References


Claims:

1. A ligand for a neuropeptide Y receptor having the formula:-
   X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15

   wherein

   X1 is H, R1-CO or one or two naturally occurring amino acids
   X2 is Leu, Ile, Val, Nle, Sar, Gly, Ala, Aib, D-Leu, D-Ile, D-Val,
   D-Ala or D-Nle;
   X3 is Arg, Lys, Orn, Ala, Dbu or His;
   X4 is His, Lys, Arg, Ala, Gly, Ser, Thr, Asn, Gln or Aib;
   X5 is Tyr, Phe, Ala, Gly, Ser, Thr, Asn, Gln or Aib;
   X6 is Leu, Ile, Val, Ala, Arg or Nle;
   X7 is Asn, Ala or Gln;
   X8 is Leu, Ile, Val, Ala, Aib or Nle;
   X9 is Leu, Ile, Val, Ala, Aib or Nle;
   X10 is Thr, Ala or Ser;
   X11 is Arg, Lys or Orn;
   X12 is Gln, Pro or Asn;
   X13 is Arg, Lys or Orn;
   X14 is Tyr, Phe, His, Trp, D-Tyr, D-Phe, D-His or D-Trp;
   X15 is OH, NH₂, NHR₂, NR₃R₄ or one or two naturally occurring
   amino acids with the terminal amino acid being in the normal or amide
   form;

   wherein R1, R2, R3 and R4 are independently alkyl groups, straight,
   branched or alicyclic in structure; and

   wherein at least one of X2 to X10 is Ala.

2. A ligand according to claim 1 wherein at least two groups selected
   from X2, X4, X5, X8 and X9 are Ala.

3. A ligand according to claim1 or claim 2 wherein X2 and X5 are
   Ala.

4. A ligand according to any one of claims 1 to 3 wherein R1 is an
   alkyl group selected from methyl, ethyl, n-butyl, t-butyl, cyclohexyl and
   other alkyl groups with 10 or less carbon atoms.
5 A ligand according to any one of claims 1 to 4 wherein R2, R3 and R4 are alkyl groups selected independently from methyl, ethyl, isopropyl, n-butyl, cyclohexyl and other alkyl groups with 10 or less carbon atoms.

6. A ligand according to any one of claims 1 to 5 which has the formula:
   Ac-Ala-Arg-Ala-Ala-Leu-Asn-Ala-Ala-Thr-Arg-Gln-Arg-Tyr-NH₂ or
   Ac-Ala-Arg-His-Tyr-Leu-Asn-Leu-Leu-Thr-Arg-Gln-Arg-Tyr-NH₂ or
   Ac-Leu-Ala-His-Tyr-Leu-Asn-Leu-Leu-Thr-Arg-Gln-Arg-Tyr-NH₂ or
   Ac-Leu-Arg-Ala-Tyr-Leu-Asn-Leu-Leu-Thr-Arg-Gln-Arg-Tyr-NH₂ or
   Ac-Leu-Arg-His-Ala-Leu-Asn-Leu-Leu-Thr-Arg-Gln-Arg-Tyr-NH₂ or
   Ac-Leu-Arg-His-Tyr-Ala-Asn-Leu-Leu-Thr-Arg-Gln-Arg-Tyr-NH₂ or
   Ac-Leu-Arg-His-Tyr-Leu-Ala-Leu-Leu-Thr-Arg-Gln-Arg-Tyr-NH₂ or
   Ac-Leu-Arg-His-Tyr-Leu-Asn-Ala-Leu-Thr-Arg-Gln-Arg-Tyr-NH₂ or
   Ac-Leu-Arg-His-Tyr-Leu-Asn-Leu-Ala-Thr-Arg-Gln-Arg-Tyr-NH₂ or
   Ac-Ala-Arg-His-Tyr-Leu-Asn-Leu-Leu-Thr-Arg-Gln-Arg-Tyr-NH₂ or
   Ac-Leu-Arg-Ala-Ala-Leu-Asn-Ala-Thr-Arg-Gln-Arg-Tyr-NH₂ or
   Ac-DLeu-Arg-Ala-Ala-Leu-Asn-Ala-Ala-Thr-Arg-Gln-Arg-Phe-NH₂ or
   Ac-DLeu-Arg-Ala-Ala-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Phe-NH₂ or
   Ac-DLeu-Arg-Ala-Aib-Leu-Asn-Ala-Aib-Thr-Arg-Gln-Arg-Phe-NH₂ or
   Ac-DLeu-Lys-Ala-Ala-Leu-Asn-Ala-Ala-Thr-Lys-Gln-Lys-Phe-NH₂ or
   Butyryl-Leu-Arg-Ala-Ala-Leu-Asn-Ala-Thr-Arg-Gln-Arg-Phe-NH₂ or
   Ac-Ala-Arg-Ala-Ala-Leu-Leu-Leu-Thr-Arg-Gln-Arg-DTyr-NH₂ or

7. A ligand according to any one of claims 1 to 6 wherein the neuropeptide Y receptor is a neuropeptide Y Y2-like receptor.

8. A ligand according to any one of claims 1 to 7 wherein the neuropeptide Y receptor is a neuropeptide Y Y2 receptor.

9. A composition for use in treatment of conditions where reduced neurotransmitter release is beneficial, in particular in relieving nasal
congestion or treating vasoconstriction predisposing to acute renal failure, anti-hypertensive conditions, cardiovascular disorders, conditions related to pulmonary congestion, inflammation, neurogenic inflammation, sleep disorders, conditions related to increased sympathetic nerve activity, diseases related to the central nervous system, conditions related to pain or nociception, diseases related to gastrointestinal motility and secretion, obesity, or Alzheimer's disease, or as an anti-psychotic, the composition including a ligand according to any one of claims 1 to 8 and a pharmaceutical carrier.

10. A method of relieving nasal congestion, attenuating cardiac vagal action, treating vasoconstriction predisposing to acute renal failure, hypertension, cardiovascular disorders, conditions related to pulmonary congestion, inflammation, neurogenic inflammation, sleep disorders, conditions related to increased sympathetic nerve activity, diseases related to the central nervous system, conditions related to pain or nociception, diseases related to gastrointestinal motility and secretion, obesity, or Alzheimer's disease in a subject, which method includes administering to the subject an effective amount of a ligand according to any one of claims 1 to 8.

11. A method of relieving nasal congestion in a subject which method includes administering to the subject an effective amount of a ligand according to any one of claims 1 to 8.

12. A method according to claim 11 wherein the composition is administered nasally.
FIGURE 1
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

Int Cl: C07K 7/08, A61K 38/10

According to International Patent Classification (IPC) or to both national classification and IPC.

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC as above

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS online subsequent search

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>WO 94/22467 A1 (UNIVERSITY OF CINCINNATI) 13 October 1994 see claims and page 16</td>
<td>1-12</td>
</tr>
<tr>
<td></td>
<td>DE 3811193 (BOEHRINGEN INGLEHEIM KG) 19 October 1989 see claims</td>
<td>1-12</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C

See patent family annex

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search: 21 JUL 1997

Name and mailing address of the ISA/AU

AUSTRALIAN INDUSTRIAL PROPERTY ORGANISATION

PO BOX 200

WODEN ACT 2606

AUSTRALIA

Facsimile No.: (06) 285 3929

Authorized officer: DAVID GRIFFITHS

Telephone No.: (06) 283 2628

Form PCT/ISA/210 (second sheet) (July 1992) copied
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
</table>
This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>WO 94/22467</td>
<td>AU 66214/94 A1</td>
</tr>
<tr>
<td></td>
<td>CN 1124927</td>
</tr>
<tr>
<td></td>
<td>EP 692971</td>
</tr>
<tr>
<td>FI 954559</td>
<td>HU 9502833</td>
</tr>
<tr>
<td>JP 08/510205</td>
<td>PL 310897</td>
</tr>
<tr>
<td>US 5604203</td>
<td></td>
</tr>
<tr>
<td>DE 3811193</td>
<td>NONE</td>
</tr>
</tbody>
</table>

**END OF ANNEX**